| Identification |
| Name: | PD 166285 |
| Synonyms: | 6-(2,6-Dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one Hydrochloride;PD 166285 |
| CAS: | 212391-63-4 |
| Molecular Formula: | C26H29Cl4N5O2 |
| Molecular Weight: | 0 |
| Molecular Structure: |
![(C26H29Cl4N5O2) 6-(2,6-Dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(...](https://img.guidechem.com/structure/212391-63-4.gif) |
| Properties |
| Biological Activity: | Potent inhibitor of the tyrosine kinases c-Src, fibroblast growth factor receptor 1 (FGFR1), and platelet-derived growth factor receptor β (PDGFR β ) (IC 50 values are 8.4, 39.3 and 98.3 nM respectively). Also inhibits the checkpoint kinases Wee1 and Myt1; abolishes Cdc2 phosphorylation in numerous tumor cell lines and abrogates the G 2 checkpoint. |
| Usage: | A broad-spectrum receptor tyrosine kinase (RTK) inhibitor which shows anti-angiogenic activity and anti-tumor efficacy in combination with photodynamic therapy (PDT). |
| Safety Data |
| |
 |
